Publications by authors named "Rory Shallis"

Claim this Profile
L
Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
Samuel J Yates, Julian J Weiss, Abigail Sneider, Emily Geramita, Guru Subramanian Guru Murthy, Rory M Shallis

Haematologica· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility, safety and outcomes of patients with newly diagnosed acute myeloid leukemia discharged 'early' after intensive induction.
Cameron J Hunter, Wei Cheng, Jan Philipp Bewersdorf, Prajwal Boddu, Sabrina Browning, Rory M Shallis

Leuk Lymphoma· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Menin inhibitors for adult acute myeloid leukemia: 2025 update.
Umar Iqbal, Julia Fadul, David A Sallman, Rory M Shallis

Expert Opin Investig Drugs· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second malignancies among older patients with classical myeloproliferative neoplasms treated with ruxolitinib.
Rong Wang, Jessica M Stempel, Rory M Shallis, Scott F Huntington, Amer M Zeidan

Blood Neoplasia· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isavuconazole provides effective and tolerable antifungal prophylaxis for patients with acute myeloid leukemia.
Cameron J Hunter, Andrew Chou, Heidi Roeder, William Eighmy, Jan Philipp Bewersdorf, Rory M Shallis

Leuk Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of older patients with TP53-mutated myeloid neoplasms.
Omer Jamy, Mobachir El Kettani, Kashish Shah, Rory M Shallis, Kendall Diebold

Blood Cancer J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
-
-Rearranged Acute Myeloid Leukemia: Pathobiology and Management Strategies.
Utsav Joshi, Rory M Shallis

Hematol Rep· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility and safety of outpatient hypomethylating agent and venetoclax initiation with and without ramp-up for newly diagnosed acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
Rory M Shallis, Julian J Weiss, Eric S Winer, Talha Badar, Alok Swaroop

Leuk Lymphoma· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heterogeneity in outcomes of TP53-mutated myeloproliferative neoplasms based on disease phenotype and mutational status.
Talha Badar, James M Foran, Jan Philipp Bewersdorf, Yu-Hung Wang, Alexander Coltoff, Rory M Shallis

Br J Haematol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world analysis of strategies to prevent thrombosis and bleeding in adults with ALL treated with asparaginase.
Joseph F Mort, David Brighton, Benjamin Mautner, Eric Pierce, Farid Ghamsari, Rory M Shallis

Blood Vessel Thromb Hemost· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avapritinib monotherapy induces rapid and deep remission of heavily treated, KIT D816H-mutated t(8;21) acute myeloid leukemia, a case report and literature review.
Ted M Getz, Kamila Bakirhan, Stuart Seropian, Rory M Shallis

Ann Hematol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the impact of stratification on the power and cross-arm balance of randomized phase 2 clinical trials.
Anna Moseley, Michael LeBlanc, Boris Freidlin, Rory M Shallis, Amer M Zeidan

Clin Trials· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Outcomes of Relapsed/Refractory Core-Binding Factor Acute Myeloid Leukemia: A COMMAND Registry Study.
Alexandra E Rojek, Benjamin J McCormick, Joanna Cwykiel, Oluwatobi Odetola, Yasmin Abaza, Rory M Shallis

Am J Hematol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab.
Jan Philipp Bewersdorf, Vanessa Hasle, Rory M Shallis, Ethan Thompson, Daniel Lopes de Menezes

Ther Adv Hematol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy.
Reid Shaw, James J Yoon, Hannah Johnston, Marta B Davidson, Alexa J Siddon, Rory M Shallis

Blood Adv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response and outcomes of patients with mutated accelerated/blast-phase myeloproliferative neoplasms.
Leah A Goldberg, James J Yoon, Hannah Johnston, Marta B Davidson, Alexa Siddon, Rory M Shallis

Blood Neoplasia· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of Enasidenib versus conventional care for older patients with mutant refractory/relapsed AML.
Abdulrahman Alhajahjeh, Kishan K Patel, Rory M Shallis, Nikolai A Podoltsev, Tariq Kewan

Leuk Lymphoma· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025.
Peter L Greenberg, Richard M Stone, Yasmin Abaza, Aref Al-Kali, Sarah Anand, Rory Shallis

J Natl Compr Canc Netw· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analyzing determinants of premature trial discontinuation in leukemia clinical trials.
Lara K Rotter, Abdulrahman Alhajahjeh, Jessica M Stempel, Alyssa A Grimshaw, Jan Philipp Bewersdorf, Rory M Shallis

Leuk Lymphoma· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A multi-institutional study.
Talha Badar, Ravi Narra, Alice S Mims, Michael G Heckman, Rory M Shallis

Am J Hematol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond HMAs: Novel Targets and Therapeutic Approaches.
Ted M Getz, Jan P Bewersdorf, Tariq Kewan, Jessica M Stempel, Aram Bidikian, Rory M Shallis

Semin Hematol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of patients with acute myeloid leukemia treated with intensive therapy after failure of venetoclax-inclusive, less-intensive therapy.
Rohan K Achar, Benjamin J McCormick, Emily Dworkin, Emily M Geramita, Annie Im, Rory M Shallis

Leuk Res· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions.
Aram Bidikian, Jan P Bewersdorf, Rory M Shallis, Ted M Getz, Jessica M Stempel

Expert Rev Anticancer Ther· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDS.
Mallory Norman, Katelyn Yamartino, Rachel Gerstein, Rory Shallis, Lourdes Mendez

Expert Rev Hematol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global Disparities in the Characteristics and Outcomes of Leukemia Clinical Trials: A Cross-Sectional Study of the ClinicalTrials.gov Database.
Abdulrahman Alhajahjeh, Lara K Rotter, Jessica M Stempel, Alyssa A Grimshaw, Jan Philipp Bewersdorf, Rory M Shallis

JCO Glob Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis